IL5RA and congenital rubella syndrome: Given the abovementioned findings, we conclude that blocking the activation of eosinophils by targeting Gαi1/3, especially via the manipulation of IL-5R pathways targeting eosinophil activation, may be useful for the treatment of CRS with high eosinophil counts and alleviate the type 2 inflammatory response.